Legal Environment and pharma industry
description
Transcript of Legal Environment and pharma industry
Legal Environment
Indian Pharmaceutical Industry
Courts
Supreme Court
High Court
District Court
Other tribunals
Company Law Board
Competition Commission of
India
Consumer Protection
Forum
Tax Tribunal
Others
Overview: Legal Environment, India
Laws are generally formulated to solve one or more of the following purposes:
To protect companies from unfair competition To protect consumers from unfair business practices To protect the interests of society from unregulated business behaviour
Structure: Indian Legal System
Evolution over the years
Early years: Indian market share was dominated by the presence of foreign companies.
99% of all drug related patents were by foreign companies.
The Turning Point, 1970: The introduction of Government control in the industry via the Indian Patent Act (IPA) of 1970.
Scrapped product patents altogether. Resulted in massive growth of local pharmaceutical companies.
1995 – WTO and the TRIPS Agreement: Introduced global minimum standards for protecting and enforcing nearly all forms of intellectual property rights (IPR), including those for patents.
Reintroduced product patents & extended protection periods to 20 years.
End of reverse-engineering , the core competence of the industry. Increase in prices of Life Saving Drugs.
Pharmaceutical Industry:Legal Aspects
Indian Laws influencing Marketing Practices
◦ The Drugs and Magic Remedies (Objectionable Advertisements) Act 1954
◦ The Indecent Representation of Women (Prohibition) Act, 1986 ◦ Consumer Protection Act, 1986
Drug Laws Prevailing in India
◦ The Drugs and Cosmetics Act 1940◦ The Pharmacy Act 1948◦ The Drugs and Magic Remedies (Objectionable Advertisements) Act
1954◦ The Narcotic Drugs and Psychotropic Substances Act, 1985
Major Laws & Regulations
In the pharmaceutical and healthcare industries, a complex web of
decision-making determines the nature of the transaction for which the direct customer of pharmaceutical industry (i.e. doctor) is responsible.
Use of medical representatives for marketing products to physicians and to exert some influence over others in the hierarchy of decision makers has been a time-tested tradition.
Aggressive marketing i.e. showering medical practitioners with expensive gifts, in return for them prescribing their drugs to patients.
Unethical practices are rampant due to the absence of any government agency to deal with this problem.
Marketing Processes & Challenges
After the implementation of the WTO-Trips Agreement, the Indian Pharmaceutical Industry has made a move to increase their R&D effort to remain competitive in the post-TRIPS environment.
Indian pharmaceutical companies are also moving in new markets aggressively, e.g. Africa & South America by the means of mergers, acquisitions & associations.
Realizing that they stand at a disadvantage w.r.t International Pharma giants in the new patent regime, Indian companies have actively started to form alliances with international pharmaceutical companies to minimize the effect of new patent regime on their drug portfolios.
Trends-Current and Future
Future Perspectives
2006 2008 2010 2012
Growth Story 9.5 11.8 13.4 15.9
13579
11131517
Sale
s,
EU
R (
bn
)
Source: Global Insight, VCI: Forecast: DB Research
Cipla have realized huge opportunity in Generic drug market as Governments are under pressure to curtail escalating healthcare expenses.
Major target market is rural India, given the low prices of drugs such as for AIDS that are available at half the price of their international versions.
Strong promotion drives in Rural India can ensure huge profits for Cipla.
Firm Focus – Cipla
THANK YOU